Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 80205

Title: Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06196079
Position: Peer Reviewer
Academic degree: MD

Professional title: Attending Doctor, Lecturer

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2022-09-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-08 03:57

Reviewer performed review: 2022-10-17 12:56

Review time: 9 Days and 8 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors wrote a review article about the nanomedicine-based multimodal therapies in colon cancer. As colon cancer is an important GI diseaes and also an important malignant disesae . The development of new treatment is promising and benefitial for the patients. The article is well written and educational. There are several points that may need further clarification. 1. There's a generalized question, how could these nano-medicine been distributed into specific colon cancer cell, by IV, PO or colonoscopy topical treatment? Nanoparticles may also elicit toxicity by disrupting membranes within the cell, how about the safety profile and potential adverse events of Nano-medicine in colon cancer treatment 1. The authors talked about anti-inflmmatory drugs, natural product's role in colon cancer, however, are they nano-medicine? Please describe more specifically and may delete them if they're not nanomedicine. Similiar question also exist in the role of metronidazole in chemotherapy. 2. In phototherapy part, H2S was also frequently noted in patients with irritable bowel syndrome and inflammatory bowel syndrome, is this treatment toward H2S focus only on colon cancer treatment or also other GI disease. 3. The authors mentioned many nanomedicine, is there any therapy which had been available in clinical practice or completed phase III clinical trial, the authors may can make a summary table of the treatments currently on phase I to phase III clinical trial, especially those on phase III clinical trial whichc is predicted to be on market soon. 5. Metastatic colon cancer is the main cause of colon cancer related mortality, the authors mentinoned about PDL-L1 blocking ability nanoparticles, what is its diffrence comparing with current anti-PD1 treatment? Is there any OTHER nanomedicne focusing on cancer cells which easily metastate or metastatic

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

cancer? Will the metastatic site influence the application of nonomedicine? 6. The authors stated that "Nanomedicine-based immunotherapy has been widely used in the treatment of colon cancer." However, the reference above are most cell and animal model. Please specify it.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 80205

Title: Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05755618
Position: Peer Reviewer
Academic degree: FACP, MD
Professional title: Doctor
Reviewer's Country/Territory: Japan
Author's Country/Territory: China

Manuscript submission date: 2022-09-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-09 05:21

Reviewer performed review: 2022-11-10 22:37

Review time: 1 Day and 17 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous
	Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The article reviewed narratively about applying nano-medicine to colonic cancer. It is an exciting report. Although several other nano-medicines for cancers have been reported, there have been no reports focusing on colonic cancer previously. Therefore, the contents of the article are fit for the journal. However, there are some concerns about this article. 1. Please describe the literature search methods. The authors could make the flowchart as a figure. 2. The number of references is small for a full review article. 3. Is there applying artificial intelligence for nano-medicine for colonic cancer? 4. Please state the primary and secondary outcomes at the end of the introduction.